Pharmacokinetics and brain uptake in the rhesus monkey of a fusion protein of arylsulfatase a and a monoclonal antibody against the human insulin receptor

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Biotechnology and Bioengineering

• Publication date

  2013-05-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/bit.24795PMID 23192358PMCID PMC3919501
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Arylsulfatase A Deficiency

  2014cited by this paper
• Selective plasma pharmacokinetics and brain uptake in the mouse of enzyme fusion proteins derived from species-specific receptor-targeted antibodies

  2012cited by this paper
• Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier.

  2012cited by this paper
• Intracerebroventricular enzyme infusion corrects central nervous system pathology and dysfunction in a mouse model of metachromatic leukodystrophy.

  2011cited by this paper
• Accumulation of lysosulfatide in the brain of arylsulfatase A-deficient mice

  2011cited by this paper
• Reversal of lysosomal storage in brain of adult MPS-I mice with intravenous Trojan horse-iduronidase fusion protein.

  2011cited by this paper
• Distribution of acid sphingomyelinase in rodent and non-human primate brain after intracerebroventricular infusion.

  2011influential reference
• Genetic engineering of a bifunctional IgG fusion protein with iduronate-2-sulfatase.

  2010cited by this paper
• Anatomy and Physiology

  2010cited by this paper
• Comparison of Blood-Brain Barrier Transport of Glial-Derived Neurotrophic Factor (GDNF) and an IgG-GDNF Fusion Protein in the Rhesus Monkey

  2009cited by this paper
• The distribution of D2/D3 receptor binding in the adolescent rhesus monkey using small animal PET imaging

  2009influential reference
• Genetic engineering of a lysosomal enzyme fusion protein for targeted delivery across the human blood‐brain barrier

  2008cited by this paper
• Genetic engineering, expression, and activity of a fusion protein of a human neurotrophin and a molecular Trojan horse for delivery across the human blood–brain barrier

  2007influential reference
• Intracerebral adeno-associated virus-mediated gene transfer in rapidly progressive forms of metachromatic leukodystrophy.

  2006cited by this paper
• The blood-brain barrier: Bottleneck in brain drug development

  2005cited by this paper
• Enzyme replacement improves nervous system pathology and function in a mouse model for metachromatic leukodystrophy.

  2005influential reference
• Accumulation of sulfatide in neuronal and glial cells of arylsulfatase A deficient mice

  2004cited by this paper
• Advances in the treatment of mucopolysaccharidosis type I.

  2004cited by this paper
• The multiple sulfatase deficiency gene encodes an essential and limiting factor for the activity of sulfatases.

  2003cited by this paper
• Subtoxic hepatic vitamin A concentrations in captive rhesus monkeys (Macaca mulatta).

  2001cited by this paper
• Brain Insulin Receptors and Spatial Memory

  1999cited by this paper
• Crystal structure of human arylsulfatase A: the aldehyde function and the metal ion at the active site suggest a novel mechanism for sulfate ester hydrolysis.

  1998cited by this paper
• Human Insulin Receptor Monoclonal Antibody Undergoes High Affinity Binding to Human Brain Capillaries in Vitro and Rapid Transcytosis Through the Blood–Brain Barrier in Vivo in the Primate

  1995influential reference
• A novel amino acid modification in sulfatases that is defective in multiple sulfatase deficiency.

  1995cited by this paper
• Compound heterozygosity for metachromatic leukodystrophy and arylsulfatase A pseudodeficiency alleles is not associated with progressive neurological disease.

  1993cited by this paper
• Capillary Depletion Method for Quantification of Blood–Brain Barrier Transport of Circulating Peptides and Plasma Proteins

  1990influential reference
• Cloning and expression of human arylsulfatase A.

  1989cited by this paper
• QUANTITATIVE ANATOMY OF THE CEREBRAL VASCULAR BED WITH ESPECIAL EMPHASIS ON HOMOGENEITY AND INHOMOGENEITY IN SMALL PARTS OF THE GRAY AND WHITE MATTER

  1965cited by this paper
• The assay of arylsulphatases A and B in human urine.

  1959influential reference

• The legacy of William M. Pardridge (1947–2024) on the science and fields concerned with the physiology of the blood-brain barrier and the transport of drugs to the brain

  2025cites this paper
• Advances in AAV-mediated gene replacement therapy for pediatric monogenic neurological disorders

  2024cites this paper
• Receptor-mediated drug delivery of bispecific therapeutic antibodies through the blood-brain barrier

  2023cites this paper
• Molecular Trojan Horses for treating lysosomal storage diseases.

  2023cites this paper
• Are TrkB receptor agonists the right tool to fulfill the promises for a therapeutic value of the brain-derived neurotrophic factor?

  2023cites this paper
• Overcoming the blood–brain barrier for the therapy of malignant brain tumor: current status and prospects of drug delivery approaches

  2022cites this paper
• A Historical Review of Brain Drug Delivery

  2022cites this paper
• Human Immortalized Cell-Based Blood-Brain Barrier Spheroid Models Offer an Evaluation Tool for the Brain Penetration Properties of Macromolecules.

  2022cites this paper
• Engineering antibody and protein therapeutics to cross the blood–brain barrier

  2022cites this paper
• Immunogenicity of MultiTEP platform technology-based Tau vaccine in non-human primates

  2022cites this paper
• IgG Fusion Proteins for Brain Delivery of Biologics via Blood–Brain Barrier Receptor-Mediated Transport

  2022influential citation
• Current treatment options and novel nanotechnology-driven enzyme replacement strategies for lysosomal storage disorders.

  2022cites this paper
• Enhancing autophagy in Alzheimer's disease through drug repositioning.

  2022cites this paper
• Blood-brain barrier delivery for lysosomal storage disorders with IgG-lysosomal enzyme fusion proteins.

  2022cites this paper
• Considerations When Developing Blood-Brain Barrier Crossing Drug Delivery Technology.

  2021cites this paper
• Novel Brain-Penetrating Single Chain Antibodies Directed Against 3RTau for the Treatment of Alzheimer's Disease and Related Dementias.

  2021cites this paper
• Organelle-level precision with next-generation targeting technologies

  2021cites this paper
• Cerebrovascular insulin receptors are defective in Alzheimer’s disease

  2021cites this paper
• Evolving new-age strategies to transport therapeutics across the blood-brain-barrier.

  2021cites this paper
• Mathematical Models of Blood-Brain Barrier Transport of Monoclonal Antibodies Targeting the Transferrin Receptor and the Insulin Receptor

  2021cites this paper
• Treating brain diseases using systemic parenterally-administered protein therapeutics: Dysfunction of the brain barriers and potential strategies.

  2020cites this paper
• New therapeutic strategies for the treatment of metachromatic leukodystrophy

  2020cites this paper
• Brain Delivery of Nanomedicines: Trojan Horse Liposomes for Plasmid DNA Gene Therapy of the Brain

  2020influential citation
• Metachromatic Leukodystrophy: Diagnosis, Modeling, and Treatment Approaches

  2020cites this paper
• Transcytosis to Cross the Blood Brain Barrier, New Advancements and Challenges

  2019cites this paper
• Targeted enzyme delivery systems in lysosomal disorders: an innovative form of therapy for mucopolysaccharidosis

  2019cites this paper
• Immunotherapy targeting toll-like receptor 2 alleviates neurodegeneration in models of synucleinopathy by modulating α-synuclein transmission and neuroinflammation

  2018cites this paper
• Strategies for Enhancing the Permeation of CNS-Active Drugs through the Blood-Brain Barrier: A Review

  2018cites this paper
• Selective targeting of 3 repeat Tau with brain penetrating single chain antibodies for the treatment of neurodegenerative disorders

  2018cites this paper
• Delivery of Biologics Across the Blood–Brain Barrier with Molecular Trojan Horse Technology

  2017cites this paper
• Investigation of Vesicular-Mediated Transport of Intercellular Adhesion Molecule-1-Targeted Carriers for Treatment of Lysosomal Storage Disorders

  2017cites this paper
• Enzymes as Immunotherapeutics.

  2017cites this paper
• Non-invasive approaches for drug delivery to the brain based on the receptor mediated transport.

  2017cites this paper
• Administrations of human adult ischemia-tolerant mesenchymal stem cells and factors reduce amyloid beta pathology in a mouse model of Alzheimer's disease.

  2017cites this paper
• Lysosomal enzyme replacement therapies: Historical development, clinical outcomes, and future perspectives

  2017cites this paper
• Brain and Organ Uptake in the Rhesus Monkey in Vivo of Recombinant Iduronidase Compared to an Insulin Receptor Antibody-Iduronidase Fusion Protein.

  2017cites this paper
• Blood–Brain Barrier: Genomics, Proteomics, Disease Targets, and Drug Delivery

  2017cites this paper
• Very High Plasma Concentrations of a Monoclonal Antibody against the Human Insulin Receptor Are Produced by Subcutaneous Injection in the Rhesus Monkey.

  2016cites this paper
• Antibody Approaches To Treat Brain Diseases

  2016cites this paper
• Concomitant Use of Neuroprotective Drugs in Neuro Rehabilitation of Multiple Sclerosis

  2016cites this paper
• Aβ-Immunotherapeutic strategies: a wide range of approaches for Alzheimer's disease treatment

  2016cites this paper
• EXAMINING GLUCOSE CONTROL AND WORKING MEMORY AS A FUNCTION OF AGE IN OLDER TYPE 2 DIABETICS: RESULTS FROM THE LOOK AHEAD BRAIN MRI ANCILLARY STUDY

  2016cites this paper
• Novel delivery methods bypassing the blood-brain and blood-tumor barriers.

  2015cites this paper
• Challenges and new strategies for therapeutic peptide delivery to the CNS.

  2015cites this paper
• Naturally Occurring Monoclonal Antibodies and Their Therapeutic Potential for Neurologic Diseases.

  2015cites this paper
• Effective treatment of glioblastoma requires crossing the blood-brain barrier and targeting tumors including cancer stem cells: The promise of nanomedicine.

  2015cites this paper
• Targeted delivery of protein and gene medicines through the blood–brain barrier

  2015influential citation
• Combined Therapies for Lysosomal Storage Diseases.

  2015cites this paper
• Aging Mechanisms

  2015cites this paper
• Passage of Humanized Monoclonal Antibodies Across the Blood-Brain Barrier: Relevance in the Treatment of Cancer Brain Metastases?

  2015cites this paper
• Immunotherapeutic Approaches Against Amyloid-β in Drug Discovery for Alzheimer’s Disease

  2015cites this paper
• Development of gene therapy for Niemann-Pick Type C disease

  2015cites this paper
• Transport of Protein and Antibody Therapeutics Across the Blood–Brain Barrier

  2015cites this paper
• Brain Effect Site Pharmacokinetics: Delivery of Biologics Across the Blood–Brain Barrier

  2015cites this paper
• Blood–Brain Barrier Targeting of Therapeutic Lysosomal Enzymes

  2015cites this paper
• Expediting the Discovery and Potential Translation of Theranostic Agents for Alzheimer's Disease

  2015cites this paper
• Insulin Receptor Antibody–Sulfamidase Fusion Protein Penetrates the Primate Blood–Brain Barrier and Reduces Glycosoaminoglycans in Sanfilippo Type A Cells

  2014cites this paper
• Gene therapy for the neurological manifestations in lysosomal storage disorders

  2014cites this paper
• Setting-up an In Vitro Model of Rat Blood-brain Barrier (BBB): A Focus on BBB Impermeability and Receptor-mediated Transport

  2014cites this paper
• A novel platform for engineering blood‐brain barrier‐crossing bispecific biologics

  2014cites this paper
• Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies

  2014cites this paper
• Immunotherapy for Alzheimer’s disease: past, present and future

  2014cites this paper
• ESCRT-mediated Uptake and Degradation of Brain-targeted α-synuclein Single Chain Antibody Attenuates Neuronal Degeneration In Vivo

  2014cites this paper
• Toward the successful delivery of lysosomal enzymes across the blood–brain barrier

  2013cites this paper
• Blood-brain barrier molecular trojan horse enables imaging of brain uptake of radioiodinated recombinant protein in the rhesus monkey.

  2013cites this paper
• Emerging therapies and therapeutic concepts for lysosomal storage diseases

  2013cites this paper
• The Application of Clinical Genetics Dovepress Recent Advances in Gene Therapy for Lysosomal Storage Disorders

  year unknowncites this paper